Burosumab 30mg/1ml solution for injection vials
NHS hospitals in England used £68,307,360 of indicative cost of Burosumab 30mg/1ml solution for injection vials in the 12 months to April 2026, about 0.3% of all hospital medicines spend. That is up 26.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Burosumab 30mg/1ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Burosumab 30mg/1ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £13,051,104 |
| Royal National Ortho.hospital Trust | £9,119,616 |
| Oxford University Hospitals Nhs Ft | £7,270,560 |
| Univ Hpls Bristol Nhs Foundation Trust | £7,010,256 |
| Alder Hey Childrens Nhs Foundation Trust | £4,802,160 |
| Sheffield Teaching Hospitals Nhs Trust | £4,434,144 |
| Manchester University Nhs Ft | £3,814,800 |
| Nottingham University Hospitals Trust | £2,809,488 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,719,728 |
| University Hospital Southampton Nhs Ft | £2,127,312 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.